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Introduction
Breast tumours are well known to be composed of pheno-
typically diverse groups of cells.  Which of these cell types
contribute to tumour development, however, is not well
understood. Two hypotheses exist: either all the cell popu-
lations have the capacity to become tumourigenic through
mutation accumulation, or this ability is confined to a
select ‘elite’ group [1]. In acute myelogenous leukaemia it
has been shown that a distinct subset of cells has
increased ability to initiate tumourigenesis and may be
identified with specific cell surface markers [2,3]. This
phenomenon has not been shown in solid tumours until
the recent publication by Al-Hajj and colleagues where
they describe a method for differentiating ‘tumour-initiat-
ing’ or ‘tumourigenic’ breast tumour cells from non-
tumourigenic cells[4].
Identification of tumourigenic breast cancer
cells
Al-Hajj and colleagues used a xenograft model in which
human breast cancer cells were grown in nonobese dia-
betic/severe combined immunodeficient (NOD/SCID)
mice. Primary cultures of breast cancer cells were
obtained from nine patients (one primary tumour and eight
metastatic pleural effusions). These cells were heteroge-
neous with respect to cell surface markers and were sepa-
rated by flow cytometry into CD44 and CD24 positive and
negative subgroups. 200,000–800,000 cells were
injected into the mammary fat pads of mice and after 12
weeks tumours had only formed in the mice injected with
CD44+ and CD24–/low cells.
Lineage markers are associated with normal cell types
(e.g. fibroblasts, leukocytes, endothelial cells and
mesothelial cells) and are not expressed by cancer cells.
By eliminating Lineage+ cells from the CD44+CD24–/low
population as few as 1000 cells consistently formed
tumours in the mouse model. Further selection for epithe-
lial-specific antigen (ESA) positive cells enriched the
tumour-initiating ability of the CD44+CD24–/low Linage–
cells even further with only 200 cells now producing
tumours in the NOD/SCID mice. ESA+CD44+CD24–/low
Linage– cells were therefore identified as the tumourigenic
breast cancer cells.
Importantly, the tumours established by the tumourigenic
breast cancer cells regained their phenotypic diversity and
contained the same heterogeneous expression of CD44,
CD24 and ESA as the original donor. On serial transplan-
tation in mice, once again, only the ESA+CD44+CD24–/low
cells were able to initiate tumours. In this way, the tumouri-
genic breast cancer cells were shown to resemble normal
stem cells in their ability to self renew, proliferate and dif-
ferentiate into diverse cell types. This phenomenon may
help explain a number of clinical observations including
the frequent finding of micrometastases in the bone
marrow of breast cancer patients that only rarely give rise
to clinically metastatic disease. These micrometastases
may be either tumourigenic or non-tumourigenic breast
cancer cells and only the tumourigenic population will be
able to progress to clinical significance.
Conclusion and future directions
Al-Hajj and colleagues have identified a critical popula-
tion of cancer cells that drive tumour growth and are
hypothesised to be the ‘stem cells’ of breast cancer.
This is a significant development and is the first time
this phenomenon has been shown in solid tumours.
Research directed at these tumourigenic breast cancer
cells to identify their unique properties will be crucial to
understanding the origin and propagation of breast
tumours. Current medical therapies directed at the
whole tumour may cause regression of the cancer, but
this new research proposes that unless they specifically
target these breast cancer-initiating cells they will not
eradicate the tumour completely. These findings open
an exciting avenue for future research and novel thera-
peutic strategies.
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